Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A bivalent anthrax vaccine

An anthrax and vaccine technology, applied in the field of immunomedicine, can solve problems such as lethal toxicity and achieve good immune effect, enhanced protective effect, excellent immunogenicity and protection.

Active Publication Date: 2020-03-27
ICDC CHINA CDC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, an ideal anthrax vaccine should contain PA, LF or EF at the same time, but this natural composition has the potential danger of lethal toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A bivalent anthrax vaccine
  • A bivalent anthrax vaccine
  • A bivalent anthrax vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] 1. Obtain a plasmid-free ΔPasteurII recipient strain (tox - ,cap - )

[0056] Bacillus anthracis Pasteur II strain (tox + / cap + ) The vaccine strain was subcultured at 37°C with shaking in a medium containing novobiocin (1 μg / μl), and the pXO2 plasmid was deleted. Then in 0.05% SDS medium containing 42 ℃ shaking continuous subculture, delete the pXO1 plasmid, obtain a strain of Bacillus anthracis completely eliminate the plasmid pXO1 and pXO2, named ΔPasteurII strain (tox - / cap - ). The results of animal toxicity tests were as follows: figure 1 As shown in A, it is confirmed that the ΔPasteurII strain has lost its virulence; capsule staining is as follows figure 1 As shown in B, it shows that the ΔPasteurII strain loses the capsule; the PCR reaction of the PagA gene on pXO1 and the capA gene on pXO2 is as follows figure 1 Shown in C, demonstrating that the ΔPasteurII strain was deleted (pXO1 - , pXO2 - ) plasmid; Western-blotting protective antigen-antibody ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a genetic engineering bivalent (rPA+rLF) anthrax vaccine.Active ingredients of the bivalent anthrax vaccine include R178A / K197A mutant protein rPA of anthrax protective antigen and R491A / L514A mutant protein rLF of a lethal factor.The vaccine is prepared from the protective antigen PA and lethal factor LF dominant biological inactivation mutant protein, the advantages are that the protective antigen PA and lethal factor LF cannot be combined, capacity of generating anthrax toxin of a natural composition and action of lethal toxicity are lost, the immunogenicity and protectiveness of the dominant biological inactivation mutant protein rPA are superior to wild protective antigen PA, and the dominant biological inactivation mutant protein rLF can stimulate an organism to increase the immune protective effect; therefore, by means of the bivalent genetic engineering vaccine, the protection effect of the mutant protein rPA is greatly enhanced, five times or more of lethal dose of the lethal toxin can be resisted to, meanwhile the biologically inactivated rPA and rLF can further compete for combining with a receptor to inhibit activity of wild toxin, the purpose of neutralizing anthrax toxin is achieved, and it is inspected to achieve a good protection effect on inhaled infection anthrax.

Description

technical field [0001] The invention relates to the field of immunomedicine, in particular to a bivalent (rPA+rLF) anthrax vaccine. Background technique [0002] Anthrax (Anthrax) is a zoonotic infectious disease caused by Bacillus anthracis infection. Herbivores (sheep, cattle, horses, etc.) are most susceptible to infection. Humans are exposed to these sick animals and their products or eat the meat of sick and dead animals. Infection is divided into skin anthrax, intestinal anthrax and pulmonary anthrax due to different routes of infection. Clinically, it mainly manifests as skin necrosis, ulcers, eschar and extensive edema of surrounding tissues, toxemia and meningitis-type acute sepsis. Once secondary infection or inhalation infection becomes pulmonary anthrax, the mortality rate is as high as 90%. More importantly, because of its high tolerance, easy production, easy storage and easy application, Bacillus anthracis is a preferred bacterial antibacterial agent. The la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/116A61K39/07A61P31/04
CPCA61K39/07A61K2039/55505A61K2039/70
Inventor 梁旭东朱进卢金星
Owner ICDC CHINA CDC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com